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Abstract 
The liver, lung, pancreas and digestive tract all originate from the endoderm germ layer and 
these vital organs are targeted by a diversity of life threatening diseases affecting millions of 
patients. However, primary cells from endodermal organs are often difficult to grow in vitro. 
For this reason, the development of protocols for generating endoderm cells and their 
derivatives has been a major a focus in the human pluripotent stem cell field. Indeed, the 
possibility to produce a large quantity of these cells by taking advantage of the unique 
properties of pluripotent stem cells and their differentiation capacity, holds great promise for 
the development of new therapeutics against global health care challenges such as diabetes 
or a diversity of infectious diseases. Here we describe recent advances in methods for 
generating endodermal cell types from human pluripotent stem cells and their use for disease 
modeling and cell based therapy.   
 
 
Introduction  
The endoderm is one of the three primary germ layers and along with mesoderm and 
ectoderm, they give rise to all adult organs. Endoderm cells are first specified through the 
process of gastrulation during early embryonic life and give rise to the gastrointestinal tract 
(gut, liver, pancreas), the respiratory system (lung and trachea) and the thyroid  (Zorn and 
Wells, 2009). All these organs have vital functions and are susceptible to life threatening 
diseases. Nonetheless, most of the endodermal cells comprising these organs are challenging 
to grow in vitro, whilst the procurement of primary tissues is often difficult and ethically 
questionable, especially from healthy donors. Consequently, a diversity of basic studies, 
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disease modeling or regenerative medicine applications are currently greatly limited by the 
lack of high quality endodermal cells. The beta cells of the pancreas and the hepatocytes of 
the liver provide an exemplar of these difficulties. Beta cells regulate glucose levels in the 
bloodstream by producing insulin and represent the main cell type targeted by diabetes. 
Despite their importance, these cells are impossible to expand in vitro, thereby limiting the 
development of new therapies such as cell-based therapy. Similarly, a diversity of drugs can 
affect hepatocytes, leading to liver injury and ultimately liver failure. Thus, liver toxicity 
represents a leading cause in drug development attrition, and toxicology screen on 
hepatocytes is an essential part of the drug screening pipeline in the pharmaceutical industry. 
However, primary hepatocyte cells lose their metabolic activity after few hours in culture, 
display a strong functional variability and remain impossible to expand in vitro, thereby 
rendering difficult a systematic and large-scale high throughput screening approach.  
     For all these reasons, the production of endodermal derivatives has been a major objective 
in the human pluripotent stem cell (hPSC) field for the past 20 years (Thomson et al., 1998). 
Indeed, hPSCs can be grown almost indefinitely in vitro while maintaining their capacity to 
differentiate into the three primary germ layers, making them the perfect candidate for 
producing endodermal cells on a large-scale. Accordingly, a broad number of groups have 
developed protocols to differentiate hPSCs into endoderm derivatives. These major efforts 
have resulted in significant progress in our capacity to produce endoderm derivatives for 
translational applications. In addition, these differentiation protocols provide a unique 
opportunity to model and study human development, especially early organogenesis. The 
current review will describe the different protocols currently available, focusing on the 
conditions and the cocktail of growth factors which are commonly utilised to generate liver, 
pancreas, gut and lung cells. We will also explore the different applications of these cells, not 
only for disease modeling and drug screening, but also for cell-based therapy and 
developmental studies. 
 
 
Protocols to Generate Definitive Endoderm Cells from hPSCs 
A diversity of protocols is now available to differentiate hPSCs into a near homogenous 
population of endoderm cells, based on fundamental principles learnt from early development. 
Gastrulation has been broadly studied in a diversity of model organisms and the basic 
knowledge accumulated has firmly established that Nodal/Activin signaling, through its 
effector SMAD2/3, orchestrates this germ layer specification. Additional signaling pathways 
are involved in this process especially WNT and FGF, which are both required for the normal 
formation of the primitive streak (Tam and Loebel, 2007) and the induction of the key 
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endoderm marker SOX17 (Kanai-Azuma et al., 2002; Tam and Loebel, 2007). Following 
gastrulation, the endoderm layer is patterned by signaling originating from the extra-embryonic 
tissues and the adjacent germ layers into a primitive gut tube comprising the foregut, hindgut 
and midgut. From these different regions the embryonic organ buds originate, which will give 
rise to functional endoderm organs. In light of this knowledge, the protocols generated 
recapitulate these key events, resulting in efficient endoderm formation from hPSCs.  
     The most commonly used method relies on growing hPSCs at near confluence on mouse 
feeders or Matrigel, in media containing small quantity of foetal bovine serum combined with 
WNT3 and a high dose of Activin (Agarwal et al., 2008; Brolén et al., 2010; D’Amour et al., 
2005; Kubo et al., 2004; Sullivan et al., 2010). Alternative methods rely on more defined media 
containing not only a high dose of Activin, but also BMP4, FGF2, the GSK3β inhibitor 
CHIR99021 and the PI3-Kinase inhibitor LY294002 (McLean et al., 2007; Nostro et al., 2011; 
Teo et al., 2012; Touboul et al., 2010). Despite their apparent divergence, these protocols 
respect the fundamental principles learnt from early development. They are based on elevated 
activation of Activin signaling, which represents the pathway necessary for inducing endoderm 
specification in a broad number of species (Tam and Loebel, 2007; Zorn and Wells, 2009). Of 
note, Nodal, which is the natural growth factor controlling endoderm differentiation during 
mouse gastrulation, is rarely used as a recombinant protein due to its poor stability and high 
cost (Schier, 2003), while GDF8 can be used as a substitute for Activin (Rezania et al., 2014). 
Similarly, whilst TGF-β is often used to maintain pluripotency of hPSCs and activates the 
SMAD2/3 signaling pathway, it is a poor inducer of endoderm differentiation. Importantly, most 
protocols of endoderm differentiation also modulate WNT pathway either by addition of 
recombinant WNT protein or the inhibition of either GSK3-β or PI3-Kinase using small 
molecules (McLean et al., 2007; Touboul et al., 2010). Moreover, most protocols start from 
colonies as opposed to single cells, since the process of EMT is inherent to the process of 
differentiation. Concerning extra-cellular matrix, endoderm differentiation can be efficiently 
performed on recombinant fibronectin or vitronectin. However, subsequent differentiation often 
requires additional ECM proteins such as collagen for hepatocytes. Thus, most protocols rely 
on relatively complex ECM.  
     These protocols result in a population expressing SOX17/GATA6/GATA4/CXCR4, while 
being negative for SOX7/SOX2/OCT4/T. The expression of FOXA2, a marker commonly used 
to characterise endoderm in the mouse, is less reliable in human, since it induction seems to 
occur after SOX17, while in the mouse, FOXA2 is a very early marker of endoderm 
specification. Homogeneity of differentiation is often confirmed by flow cytometry analyses for 
the expression of the cell surface marker CXCR4. Importantly, the resulting endoderm 
progenitors described by some protocols can be maintained for a prolonged period of time, 
while maintaining their capacity to differentiate into a diversity of endodermal derivatives 
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including pancreas, liver, gut and lung (Gadue et al., 2005; Hannan et al., 2013a; Pagliuca et 
al., 2014). Overall, methods to generate endoderm cells from hPSCs are converging and there 
is now a clear consensus concerning the growth factors and the culture conditions necessary 
to direct hPSC differentiation toward this lineage (Table 1). 
 
 
Differentiation of hPSCs into Endoderm Derivatives  
 
Hepatocytes 
The liver is a unique organ by the broad spectrum of its function. The liver sustains reserves 
of iron, vitamins and minerals. It detoxifies alcohol, drugs and other chemicals as well as 
removing inhaled poisons such as exhaust or smoke. The liver also produces bile for digestion 
of lipids, albumin (Alb) which represents the most abundant protein in the plasma, and blood 
clotting factors. Finally, the liver has an essential metabolic activity by storing glycogen and 
lipids. Most of these functions are fulfilled by hepatocytes, which represent 80-90% of the cells 
of the liver. Due to their broad function and interest of the pharmaceutical industry, the 
production of hepatocytes has been a key focus in the hPSC field, resulting in the development 
of a diversity of protocols to achieve this goal. These methods follow a normal path of 
development starting with endoderm specification, followed by patterning of the endoderm into 
foregut using Activin. Hepatoblast-like cells are then produced by blocking Activin and adding 
BMP4/FGF which are known to control liver bud formation in vivo. The resulting progenitors 
are then differentiated into hepatocytes using a diversity of media frequently, if not 
systematically, supplemented with Hepatic Growth Factor (HGF) and Oncostatin M (OSM), 
two growth factors known to be involved in liver development and functional maturation 
(Agarwal et al., 2008; Brolén et al., 2010; Cai et al., 2007; Chen et al., 2012; Hannan et al., 
2013b; Mallanna and Duncan, 2013; Si-tayeb et al., 2010; Siller et al., 2015; Song et al., 2009; 
Sullivan et al., 2010; Touboul et al., 2010). The longer the cells are then grown in these 
conditions, the more their metabolic activity seems to increase and this phase of functional 
maturation can last up to 20-30 days with some protocols (Agarwal et al., 2008; Brolén et al., 
2010; Hannan et al., 2013b; Mallanna and Duncan, 2013). Hepatocytes produced from hPSCs 
express key transcription factors and functional markers such as HNF4α, HNF6, CEBPα, 
PROX1, GATA4 and ALB, AAT and CYP3A4 respectively. These hepatocyte-like cells (HLCs) 
were also shown to have liver-specific functions such as albumin secretion, glycogen 
synthesis, urea production, LDL uptake and limited cytochrome P450 activity (Agarwal et al., 
2008; Brolén et al., 2010; Cai et al., 2007; Hannan et al., 2013b; Mallanna and Duncan, 2013; 
Si-tayeb et al., 2010; Song et al., 2009; Sullivan et al., 2010). Nonetheless, HLCs are not 
5 
 
equivalent to primary adult hepatocytes and in fact more closely resemble foetal hepatocytes. 
Indeed, they express markers such as AFP and do not express adult CYP450 including 
CYP3A4 to the same extent as primary freshly isolated hepatocytes (Baxter et al., 2015). 
Thus, a broad number of approaches have been developed to further increase their metabolic 
function including the use of Vitamin C, 3D co-culture (Gieseck et al., 2014; Takebe et al., 
2014) and small molecules (Shan et al., 2014). Nonetheless, none of these methods appear 
to result in the production of hepatocytes displaying the full range of adult functionality, while 
the transfer of these methods between laboratories has been challenging. Consequently, 
differentiation protocols have not fundamentally changed over the past 5 years. This lack of 
progress can also be explained by the scarcity of knowledge regarding hepatic functional 
maturation which happens very progressively after birth. Indeed, this stage is particularly 
difficult to study in human for obvious ethical reasons while study in animal models remains 
limited. Consequently, we have little information regarding the signaling pathways and factors 
controlling hepatocyte maturation in vivo. Furthermore, culture media currently available to 
grow primary hepatocytes only allows the maintenance of metabolic functions for few days if 
not hours. Consequently, even a successful process of differentiation is unlikely to generate 
functional cells for more than few hours. Importantly, the lack of maturity of HLCs does not 
imply that these cells cannot be used to model disease or transplantation (See below). On the 
contrary, their foetal nature could provide them with advantageous properties of proliferation 
and plasticity. Nonetheless, the lack of metabolic activity denotes major limitations for drug 
toxicity screening especially in the context of the pharmaceutical industry. In summary, the 
production of hepatocyte-like cells from hPSCs can be now robustly achieved using methods 
broadly available and despite their imperfection, the resulting cells have a direct interest for a 
diversity of clinical applications. Nonetheless, the production of fully functional hepatocytes 
continues to be a major objective and a better understanding of liver development in human 
will be essential to bypass the limitation of the current protocols.  
 
 
Cholangiocytes 
Cholangiocytes represent the second cell type of the liver which has an endodermal origin. 
These cells form the epithelium of the biliary three and have a key function in bile transport, 
inflammation and liver repair. Both hepatocytes and cholangiocytes originate from 
hepatoblasts, a common progenitor found in the liver bud during early hepatic development 
(Shan et al., 2014). Thus, protocols for cholangiocyte production follow hepatocyte 
differentiation up to the production of hepatoblasts which are then differentiated into 
cholangiocyte progenitors by modulating Notch signaling and/or TGF-β. Subsequently, these 
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cells are grown in a 3D environment in the presence of growth factors such as 
EGF/HGF/FGF10 or in co-culture with cells expressing NOTCH. The resulting cholangiocytes 
express biliary markers such as CK18, CK19, SOX9, HNF1B, γ-glutamyl transferase (GGT1), 
NOTCH2, CFTR, SCR, SSTR2 and AQP1 (Dianat et al., 2014; Ogawa et al., 2015; 
Sampaziotis et al., 2015a). Most importantly hPSC-derived cholangiocytes display operational 
MDR1 receptor, CFTR chloride transporter activity, GGT secretion as well as  ALP activity 
(Ogawa et al., 2015; Sampaziotis et al., 2015a). Finally, they react to hormone stimuli and can 
transport bile acid. Transcriptomic analyses confirmed their biliary identity but also revealed 
that these cells continue to express foetal markers such as SOX9, suggesting that similarly to 
hepatocytes, hPSC-derived cholangiocytes are not equivalent to primary adult cells. Despite 
these limitations, these cells have been shown to model accurately genetic cholangiopathies 
such as Alagille’s Syndrome and polycystic liver disease (Sampaziotis et al., 2015a). In 
addition, cholangiocytes generated from hPSCs carrying a mutation in the CFTR gene have 
been proven useful to validate drugs for the treatment of Cystic Fibrosis in the liver (Ogawa et 
al., 2015; Sampaziotis et al., 2015a). Thus, similarly to hepatocytes, hPSC-derived 
cholangiocytes can be useful for translational applications as well as for basic biology studies.  
 
Pancreas 
Production of pancreatic β-cells from hPSCs has been explored extensively due to the great 
promise they hold for cell therapy against diabetes. Indeed, β-cells which secrete insulin upon 
glucose stimulation are the main target of the immune system in Type 1 diabetes, while there 
is growing evidence that their exhaustion/dedifferentiation has a major role in Type 2 diabetes. 
In parallel, transplantation of pancreatic islets which are the functional unit of the pancreas 
containing β-cells has been shown to be efficient in patients with end stage disease to restore 
controllable glycemia, and even in some cases to allow independence from insulin injection. 
Nonetheless, only a limited number of patients can benefit from this therapy since it relies on 
a large number of islets which can only be obtained from 2-3 cadaveric donors. Thus, major 
funding initiatives from industry, governmental and charity organisations have supported 
ambitious programs aiming to produce pancreatic cells from hPSCs. The combination of 
strong financial support and extensive existing knowledge on pancreatic development allowed 
the creation of differentiation protocols which are probably the most advanced in the endoderm 
field. These protocols are based on a stepwise differentiation which closely mimics embryonic 
development. In summary, culture conditions are changed every 2-4 days to attain a new 
stage of differentiation, marked by the expression of a specific combination of markers which 
have been functionally validated in model organisms. The first step after endoderm formation 
involves the induction of posterior foregut (FOXA2/HNF1B/HNF4A) using FGF7 (or KGF) 
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(D’Amour et al., 2006; Pagliuca et al., 2014; Rezania et al., 2014). Pancreatic progenitors 
(PDX1/NKX6.1/SOX9) are then obtained by adding Retinoic Acid and FGF7 while inhibiting 
BMP, TGF-β and SHH signaling (D’Amour et al., 2006; Pagliuca et al., 2014; Rezania et al., 
2014). Importantly, Activin/TGF-β can also be used to increase the number of cells expressing 
NKX6.1 (Nostro et al., 2015) which is essential to obtain truly multipotent pancreatic 
progenitors. Endocrine progenitors (PDX1/NGN3/NeuroD1) are then induced by inhibiting the 
TGF-β receptor ALK5 in the presence of thyroid hormone. Further differentiation into β-like 
cells (INS+) is obtained by growing endocrine progenitors in the presence of a combination of 
Notch, SHH inhibitors and the receptor tyrosine kinase AXL inhibitor (Pagliuca et al., 2014; 
Rezania et al., 2014). The resulting β-cells can secrete insulin upon glucose stimulation in 
vitro while they rescue animal model for diabetes. Importantly, inhibition of ALK5 seems to be 
essential for avoiding the production of multi-hormonal cells which are known to represent 
immature cells with limited function (Rezania et al., 2014). Despite these significant advances, 
the resulting cells display a glucose response comparable to those foetal cells. Furthermore, 
these protocols are often cell line dependent, meaning that they work more efficiently on the 
cell lines originally used for their development. Nonetheless, hiPSC-derived pancreatic cells 
have been proven useful for modeling  disease (see next section) and have enabled the 
creation of platforms for drug screening (Pagliuca et al., 2014). Finally, the biotech company 
Viacytes has pioneered a clinical trial to define the interest of pancreatic progenitors 
(PDX1/NKX6.1/SOX9) for cell based therapy (See below). Thus, pancreatic cells currently 
generated from hPSCs display a level of function which is likely to be sufficient for a diversity 
of applications including drug screening and regenerative medicine. Nonetheless, there is no 
doubt that the field is already working to further improve the functional profile of β-like cells 
currently available. 
 
 
Lung 
Pulmonary disease is the third leading cause of death worldwide and many of these conditions 
are currently without treatment. Despite this major healthcare challenge, production of lung 
cells from hiPSCs has only recently become a major focus with systematic studies performed 
to identify conditions to generate airway cells. The diversity of signaling pathways known to 
control lung endoderm specification, the cellular complexity of this organ as well as the close 
interplay with thyroid development has been a great challenge for the development of 
protocols for the production of lung cells. Nonetheless, several directed differentiation 
protocols have now managed to very efficiently produce lung and airway epithelial cells (Dye 
et al., 2015; Firth et al., 2014; Gotoh et al., 2014; Huang et al., 2013; Longmire et al., 2012; 
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McIntyre et al., 2014; Wong et al., 2012). These protocols start with patterning of endoderm 
cells into anterior foregut by inhibiting Activin and BMP signaling. Further stimulation of WNT, 
SHH, BMP4 and FGF7/10 signaling results in the acquisition of an identity of early lung 
epithelial progenitors expressing the master regulator NKX2.1. Alternatively, Wong and 
colleagues used a combination of FGF7, FGF10 and low concertation of BMP4 without direct 
modulation of WNT. The  resulting progenitors can differentiate into cells expressing markers 
of proximal airway epithelium including FOXJ1, CFTR and MUC16 after cultured in air-liquid 
interphase condition for 5 weeks,  (Wong et al., 2012). Further refinement of this protocol  has 
improved the production of ciliated, Clara and goblet cells in vitro and in vivo with the caveat 
that the cultures are contaminated with mesodermal and neuronal cell types (Huang et al., 
2013).  
     Despite these apparently divergent protocols, recent studies have clearly established that 
WNT signaling is essential to block thyroid cell specification expressing NKX2.1/PAX8, which 
are closely related to lung progenitors during early development (Serra et al., 2017). 
Furthermore, WNT was also shown to control the proximodistal patterning of lung endoderm 
(NKX2.1+/PAX8-). Of note, differentiation protocols often yield a heterogeneous mixture of 
lung and non-lung cell types while the lung epithelial cell types can range from basal stem 
cells of the proximal region to alveolar epithelial cells (AECs) from the distal region. This 
comes to importance when studying disease. For example, some pulmonary disorders affect 
specific lung epithelial cell types or regions but not others. The proximal region of the lung is 
most afflicted in Cystic Fibrosis and therefore the specific derivation of proximal lung epithelial 
from human pluripotent stem cells would be most suitable for disease modeling or drug 
screening in this instance. Consequently, recent protocols rely on cell sorting, taking 
advantage of cell surface makers CD47hi/CD26low to purify NKX2.1-expressing lung 
endoderm cells. Using this approach, McCauley and colleagues identified conditions of “low 
WNT levels” which favour the differentiation of these lung endoderm cells (NKX2.1+/SOX2+) 
into proximal lung cell fates while high WNT levels favour the production of progenitors 
(NKX2.1+/SOX9+) for distal airway cells (McCauley et al., 2017). Motile cilia were observed 
when these proximal lung epithelial cells were cultured in 3D with Notch inhibitors or in an air-
liquid interface (ALI). The authors also demonstrated the potential of these cells in Cystic 
Fibrosis disease modeling and drug screening by showing that these proximal cell types can 
form organoids in 3D culture conditions which are able of undergoing CFTR-dependent 
forskolin-induced swelling.  
     Importantly, the difficulty to isolate and then maintain the functional characteristics of 
primary lung cells in vitro, has limited the direct comparison necessary to establish the exact 
level of maturation of hiPSC-derived lung cells. Furthermore, simple and quantitative standard 
assays for evaluating the functionality of lung cells remain to be established. Evaluation of 
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mucin secretion and surfactant production could be systematically applied, while 
electrophysiology to measure short circuit current on cells grown in air liquid interface could 
also provide more qualitative functional measurement. Interestingly, methods based on new 
imaging technologies are currently under development for measuring cilia beat frequency and 
such approach could provide new perspective on phenotyping lung cells. Finally, animal 
models for lung injury have just become available to test engraftment and function of cells 
generated in vitro (Dye et al., 2016; McIntyre et al., 2014; Miller et al., 2017; Nikolić et al., 
2017). In this context, a recent study has described the generation of lung SOX9+ bud tip-like 
progenitor cells which have the capacity to differentiate into multiple lineages both in vitro and 
in vivo providing of proof of principle for engraftment of hPSC-derived cells following lung injury 
(Miller et al., 2017). 
     To conclude this part, the lung field has developed robust methods for directing the 
differentiation of hPSCs into a diversity of lung cells which will be very useful to uncover 
mechanisms controlling embryonic development and disease. The production of these cells 
could also open the possibility to cell based therapy applications which have been relatively 
unexplored until now. 
 
 
Gastrointestinal Tract 
The gastrointestinal tract has a complex and diverse set of functions such as digesting food, 
absorbing nutrients and energy as well as providing immune protection. There is a rising global 
incidence of diseases affecting the gastrointestinal tract a well as an increase of patients 
lacking gastrointestinal function altogether; there is therefore a high demand for effective 
models of human intestinal development, disease and regeneration to improve our 
understanding of their aetiology, and screening of potential therapeutics for inflammatory 
bowel disease and intestinal transplant for short gut syndrome. To address this objective,  
human intestinal organoids (HIOs) have been successfully generated from hPSCs using 
different approaches that mainly rely on driving differentiation of endoderm cells into 
mid/hindgut using WNT and FGF (Hannan et al., 2013a; Spence et al., 2011). The resulting 
cells are then grown in 3D culture conditions, as had been previously established for primary 
gut organoids (Sato et al., 2009). These organoids rely on EGF, R-Spondin and WNT signaling 
modulation, as well as extracellular matrix support from collagen and laminin rich gels such 
as Matrigel. Whilst Matrigel provides an excellent basement matrix for organoid growth, there 
is variation in the characteristics of the matrix, as well as contamination with various cytokines. 
Recent efforts have been made to switch to more reproducible and defined synthetic gels, 
improving the potential of these organoids to be used in regenerative medicine (Cruz-Acuña 
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et al., 2017). Importantly, the method used to reach the first step of the protocol has a major 
impact on the subsequent organoids generated. Indeed, methods allowing a near 
homogeneous population of endoderm cells results in gut organoids that closely resemble 
organoids derived from foetal tissue (Fordham et al., 2013) which can be grown almost 
indefinitely in vitro and which can acquire expression of functional markers over time 
(Forbester et al., 2016). On the other hand, the most established and characterised system 
by Wells and colleagues allows the production of endoderm cells contaminated by a small 
fraction of mesoderm cells. These cells, when grown in 3D conditions, form a mesenchyme 
layer supporting differentiation, organisation and functional maturation of gut cells. Of note, 
this co-culture system allows only a limited number of passaging and is thus not compatible 
with large scale amplification the cells. Nonetheless, hiPSC-derived intestinal-like structures 
are highly proliferative, express the characteristic markers of the intestinal epithelium including 
functional markers such as lysozyme and mucins, the intestinal transcription factors KLF5, 
CDX2 and SOX9 as well as the stem cell markers LGR5 and ASCL2 (Spence et al., 2011). 
The organoids contain the main cell types comprising the adult intestinal epithelium including 
enterocytes, goblet cells, Paneth cells and enteroendocrine cells. Functional analysis of the 
gene NGN3 in these organoids, showed that its knockdown results in loss of enteroendocrine 
cells whereas its overexpression leads to 5-fold higher levels of endocrine cells (Spence et 
al., 2011). This study provides a proof of principle that the intestinal organoids provide a 
powerful tool to study gene function and their role in disease development. Nonetheless, it is 
important to underline that HIOs still exhibit a gene expression profile similar to foetal cells, 
while the functionality of these organoids can be further increased by transplantation under 
the kidney capsule of immune deficient mice (Watson et al., 2014).  
     The initial organoid systems appeared to represent the proximal small intestine, with 
subsequent attempts to optimise protocols to derive other regions of the gastrointestinal tract. 
Gastric organoids were generated using WNT3A, CHIR99021, and Noggin to generate foregut 
from definitive endoderm, followed by FGF4, Noggin, and finally retinoic acid to generate 
gastric organoids that express key markers such as SOX2, PDX1, GATA4 and KLF5 
(McCracken et al., 2014). More recently, attempts were made to direct intestinal organoids to 
a more colonic nature (Munera et al., 2017), using BMP to generate organoids that express 
colonic epithelial markers and can produce colon-specific cell types after engraftment in the 
kidney capsule. However, transcriptome wide analysis has shown limited similarity to in vivo 
tissue, and there is still much scope for optimisation of all systems to greater physiological 
maturity. This lack of maturity of the model can also be turned to advantage, allowing further 
differentiation of the systems to specific intestinal regions, and exploring development 
(Finkbeiner et al., 2015; Tsai et al., 2017). 
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     Overall, the development of protocols of hPSCs-derived gut organoids has been 
remarkable by its rapid progress and its diverse applications in disease modeling and 
developmental studies, and represents a highly promising tool in regenerative medicine. 
However, further optimisation of the model is needed, to more closely resemble mature region-
specific areas of the gastrointestinal tract, particularly on a transcriptome and epigenome wide 
level (Table 2 and Figure 1).  
 
 
Endoderm Differentiation of hPSCs as an in vitro Model of Development 
While translational applications have been the main driver to develop protocols for 
differentiating hPSCs into endoderm, these methods have also been useful to uncover 
molecular mechanisms directing this early cell fate decision during development. Indeed, in 
vitro hPSC differentiation recapitulates developmental processes and waves of expression of 
key transcription factors, thereby providing a unique opportunity for studying mechanisms 
impossible to study otherwise, especially in human. This aspect is particularly important in 
view of the recent observations that despite significant conservation, the mechanisms 
controlling cell fate decisions could also show divergence even between mammalian species 
such as human and mouse. As an example, recent reports have shown that GATA6 is 
necessary for endoderm differentiation and pancreatic development in hPSCs (Fisher et al., 
2017; Shi et al., 2017; Tiyaboonchai et al., 2017) while heterozygous mutation in humans 
results in pancreatic agenesis. On the other hand, this mutation has no effect on pancreas 
development in the mouse. Only the combined absence of GATA6 and GATA4 seems to affect 
mouse pancreatic organogenesis (Carrasco et al., 2012; Xuan et al., 2012). Interestingly, 
GATA6 could be controlled by the WNT pathway through its interaction with LEF1 in human 
endoderm cells (Sun et al., 2017) suggesting additional divergence at the signaling pathway 
level. Thus, transcriptional networks controlling early endoderm differentiation could vary 
between species. hPSC endoderm differentiation has also been used to perform studies 
impossible or challenging with model organisms. As an example, ChIP-seq analyses have 
revealed the extend of the network controlled by SMAD2/3 during endoderm differentiation  
and also their cooperation with the transcription factor EOMES and epigenetic modifiers 
JMJD3 (Brown et al., 2011; Kim et al., 2011). Recent studies also confirm that pluripotency 
factors such as OCT4 cooperate with signaling pathways to enable the expression of 
endoderm markers (Ying et al., 2015). Interestingly, comparative analyses between in vitro 
data and studies in the mouse, suggest that EOMES function in endoderm could be conserved 
between species (Teo et al., 2011). Further analyses have uncovered the cross talk between 
PI3-Kinase, WNT and TGF-β (Singh et al., 2012), while other studies have uncovered the 
epigenetic regulations directing endoderm differentiation including the mechanisms by which 
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SMAD2/3 could direct the activity of MLL complexes through its interaction with DPY30. 
Interestingly, genetic studies in the mouse suggest that similar interplays between DPY30 and 
SMAD2/3 could also take place in vivo (Bertero et al., 2015) thereby demonstrating that 
hPSCs can be useful to inform evolutionary conserved mechanisms controlling gastrulation.  
     On the other hand, hPSC differentiation into endoderm can be exploited to uncover novel 
mechanisms which are either masked by functional redundancy in vivo and/or are only 
relevant for human development. As an example, detailed molecular analyses has revealed 
that endoderm specification is controlled by interplays between SMAD2/3 and the cell cycle 
regulators Cyclin D/CDK4/6 (Pauklin and Vallier, 2013). Furthermore, the same cell cycle 
regulators seem to orchestrate the recruitment of transcriptional regulators and epigenetic 
modifiers on endoderm genes (Pauklin et al., 2016). These mechanisms suggest that the cell 
cycle machinery directly orchestrates cell fate decisions in hPSCs. However, knockout of 
these cell cycle regulators in the mouse embryo has no effect on gastrulation, thereby 
suggesting these mechanisms could be either more important in vitro or human specific. 
     Importantly, hPSCs are also frequently used to uncovered mechanisms controlling 
development of endoderm organs. In vitro differentiation has been applied to study the function 
of a diversity of transcription factors and signaling pathways controlling pancreatic (Cebola et 
al., 2015; Kee et al., 2015; Zhu et al., 2016)  or hepatic development (DeLaForest et al., 2011). 
Similarly, hPSCs have been used to uncover the signaling pathways controlling lung or 
intestinal specification from endoderm in human (Chen et al., 2017; Huang et al., 2013; 
McCauley et al., 2017; Serra et al., 2017; Snoeck, 2015). Thus, hPSCs offer unprecedented 
opportunities to study human organogenesis. 
     Taken together, these studies have uncovered new molecular mechanisms regulating 
human endoderm formation and its derivatives, and thus demonstrate the importance of hPSC 
as a model system to not only validate known molecular mechanisms, but also to uncover new 
aspects of embryonic development.   
 
 
Disease Modeling Using Endoderm Derivatives 
The remarkable advances in the development of protocols for generating a repertoire of 
endoderm derivatives in vitro has been associated with translational applications which can 
be divided in 2 groups: Disease modeling/drug screening and cell based therapy (Figure 2). 
 
Genetic Disorders 
A broad number of inherited diseases has been modelled using endodermal derivatives. Of 
particular interest, the liver received great attention in recent years due to various genetic 
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disorders, alcohol induced and non-alcoholic fatty liver disease, hepatotropic infections and 
drug-mediated toxicity. Accordingly, a diversity of reports have shown that hepatocytes 
derived from hiPSCs can be used to model a variety of disorders including inherited metabolic 
disorders (IMDs) such as α1-antitrypsin deficiency (A1ATD), familial hypercholesterolemia 
(FH), glycogen storage disease type 1a (GSD1a) and Wilson’s disease (WD) (Cayo et al., 
2012; Sampaziotis et al., 2015b; Yusa et al., 2011; Zhang et al., 2011). Successful modeling 
of monogenetic disorders has also been achieved with hiPSC-derived cholangiocytes (Ogawa 
et al., 2015; Sampaziotis et al., 2015a) and lung cells for Cystic Fibrosis (Wong et al., 2012). 
Importantly, those culture systems have also been used to screen drugs for hepatic 
maturation, hepatoxicity (Hannoun et al., 2016), control of cholesterol levels (Cayo et al., 
2017), Cystic Fibrosis (Sampaziotis et al., 2015a; Wong et al., 2012), α1-antitrypsin deficiency 
(Choi et al., 2013)  or even neonatal diabetes (Zeng et al., 2016). 
     HPSC-derived intestinal organoids also present a great opportunity for exploring intestinal 
pathophysiology using genetically modified PSC lines. For example, deriving iPSCs from 
patients with dyskeratosis congenita (DC) and gene correction by CRISPR/Cas9, enabled 
disease modeling and pathway interrogation using the organoid model (Woo et al., 2016). 
Similarly, hiPSC-derived intestinal organoids have been used to model Hirschsprung's 
disease caused by a mutation in the gene PHOX2B. In this last study, hiPSCs lines with 
mutations in PHOX2B were differentiated into neural crest cells and combined with HIOs. 
Further transcriptional analysis revealed downregulation of genes relevant to muscle 
development in organoids carrying the genetic anomaly (Workman et al., 2016). These results 
provide of proof of concept that HIOs could be useful to further shed light on the molecular 
mechanisms driving disease.  
     Finally, pancreatic cells have been used by a broad number of studies to model a genetic 
form of diabetes (MODY) or pancreatic agenesis (Teo et al., 2013). Overall these reports show 
that hPSC-derived pancreatic cells can be used to model genetic disorders affecting 
pancreatic development including mutations in HNF1b (Teo et al., 2016), GATA6 (Fisher et 
al., 2017; Shi et al., 2017; Tiyaboonchai et al., 2017), PDX1 (Kee et al., 2015; Zhu et al., 2016), 
NGN3 (Zhu et al., 2016) and β-cell function (Zeng et al., 2016). Importantly, such a model 
could be used advantageously to uncover the mechanisms by which haploinsufficiency 
induces diabetes in humans and will ultimately help to functionally validate the diversity of 
genetic variants associated with diabetes by GWAS studies. 
     Accordingly, several consortia have generated large scale banks of hiPSC lines (Soares et 
al., 2014) to study human genetic diversity in a dish. Of particular interest, the NextGen 
consortium (Warren et al., 2017a) has shown that a large cohort of hiPSC lines differentiated 
into hepatocytes could allow the identification of new expression Quantitative Trait Loci (eQTL) 
involved in lipid metabolism (Pashos et al., 2017) and also to validate the function of genetic 
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variants identified by Genome Wide Association Studies (GWAS) (Warren et al., 2017b). Of 
note, hiPSC lines have also been generated from patients with Type 1 (Chen et al., 2009) and 
Type 2 (Ohmine et al., 2012) diabetes without revealing a clear phenotype after differentiation. 
Nonetheless, these studies were based on a limited number of cell lines while large scale 
experiments could be informative in uncovering novel genetic mechanisms driving diabetes. 
Taken together, these studies demonstrate the feasibility of using endoderm derivatives to not 
only model monogenetic disorders affecting endodermal organs, but also to study genetic 
mechanisms controlling the onset and penetrance of complex disorders.  
 
 
Infectious Disease   
Endodermal organs are also the target of major infectious diseases such as malaria and 
hepatitis. Thus, modeling these diseases using their cellular target such as liver cells has 
attracted a lot of attention in recent years. Accordingly, several groups have shown that hiPSC-
derived hepatocytes can support the Hepatitis C virus (HCV) life cycle including replication, 
release of infectious virions and an inflammatory response to the infection (Carpentier et al., 
2014; Schwartz et al., 2012). Interestingly, microarray analyses of non-permissive cells and 
permissive cells for infection, has revealed upregulation of known cofactors supporting virus 
infection and downregulation of antiviral genes, providing a platform for further identification 
of key genes involved in survival of the virus, and potential therapeutic applications (Wu et al., 
2012). hPSC-derived hepatocytes were also successfully infected with HBV (Shlomai et al., 
2014) or Plasmodium parasites which cause malaria (Ng et al., 2015). The common caveat 
with these studies is the low infection and replication rate of the pathogens. This limitation 
could be attributed to immaturity of the host hepatocytes, highlighting the importance of further 
improvement of current differentiation protocols. HIOs have also been used to model the 
interface of the intestine with infectious agents such as interaction of Salmonella enterica 
serovar Typhimurium with intestinal epithelium (Forbester et al., 2015).  This study shows that 
the bacteria could infect hiPSC-derived intestinal cells while provoking a change in expression 
profile indicating the initiation of a pro-inflammatory response. Additionally, HIOs have been 
used to study more physiological colonisation of the gut, and how this might affect 
development, taking advantage of the relative immaturity of the model (Woo et al., 2016). 
Similarly, hPSC-derived gastric organoid infection by H. pylori results in the rapid association 
of the virulence factor CagA with the c-Met receptor inducting epithelial cell proliferation 
(McCracken et al., 2014). These data clearly establish the interest of hPSC-derived gut cells 
to model host-pathogen interaction. Finally, there is no doubt that hPSC-derived lung cells will 
soon be used as a model for infections of the lung tissue.  
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     Overall, hPSC-derived endodermal cells have demonstrated their importance and capacity 
to model a diverse set of diseases and certainly represent a complementary if not an 
advantageous alternative to previous systems. Nonetheless, these platforms are just starting 
to be exploited to uncover new mechanisms of disease and the transfer of this technology to 
more disease-oriented laboratories will certainly accelerate their exploitation for clinical 
application. 
 
 
Cell-based Therapy 
The second major translational application of endoderm derivatives is cell-based therapy. 
Indeed, multiple diseases affecting organs originating from the endoderm layer could be 
treated if not cured using cell replacement therapy. Accordingly, primary hepatocytes have 
already been transplanted into nearly 100 patients to treat a variety of inherited liver diseases 
including A1ATD, glycogen storage disorders (GSD), Crigler-Najjar syndrome and factor VII 
deficiency. Unfortunately, cell-based therapy of the liver is limited by the scarce number and 
quality of available donor cells. Therefore, a broad number of studies have analysed the 
capacity of hPSC-derived hepatocytes to colonise the liver and restore vital functions in animal 
models for liver failure. Interestingly, these studies have shown variable results depending on 
the type of liver injury. For instance, liver colonisation and rescue of the fumarylacetoacetate 
hydrolase (Fah)-mice which provide a model for inherited metabolic disorders, remains 
extremely challenging with hPSC-derived hepatocytes, while they represent the gold standard 
for primary adult hepatocyte transplantation. Other models such as the uroplasminogen 
activator (uPA) mice which mimic acute liver failure have been successfully engrafted with 
hPSC-derived hepatocytes but the persistence of the transplanted cells was limited to few 
weeks (Touboul et al., 2010). Finally, the best results have been obtained with liver injuries 
induced by chemical modeling of liver cirrhosis such as tetrachloride or paracetamol treatment. 
In these experiments, hPSC-derived hepatocytes were able to colonise more than 5-10% of 
the liver while improving mice survival (Cai et al., 2007; Chen et al., 2015; Liu et al., 2011; 
Tolosa et al., 2015).  
     Considered together, these results demonstrate that hPSC-derived hepatocytes could be 
used in cell based therapies targeting specific liver pathology. Indeed, these cells could be a 
useful therapy in the context of acute liver failure induced by drug induced liver injury for 
example. Nonetheless, such application will require a large number of cells which could be 
challenging to produce in GMP conditions. In addition, the injection of such number of cells 
will have to be done in the portal vein and thus could result in cells engrafting in other organs. 
Thus, risks associated with uncontrolled growth and teratoma formation will have to be 
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carefully monitored. Finally, such approach might not work for a majority of end stage liver 
diseases which involve important remodelling of the liver architecture due to fibrosis/cirrhosis. 
     For these reasons, alternative approaches to intra-hepatic transplantation are currently 
explored including the transplantation of bags or patches containing liver cells (Stevens et al., 
2017).  As an example, hPSC-derived hepatoblasts combined with mesenchymal stem cells 
and endothelial cells in a 3D patch of Matrigel have been shown to rescue TK-NOG mice 
(Takebe et al., 2014). Thus, extra-hepatic transplantation could also provide an interesting 
alternative to treat liver failure. However, such approach has also its own limitations since the 
3D patch requires extensive spontaneous vascularisation to be plugged to the blood flow, 
while the absence of connection with the biliary system will be problematic to evacuate toxic 
bile. Thus, while promising, cell-based therapy using hiPSC-derived liver cells still requires 
new innovations which could involve the in vitro generation of mini-livers using decellularized 
organs (Pla-Palacín et al., 2017). In addition, a step by step clinical strategy with systematic 
testing in animals will help to address the challenges associated with safety and intra-hepatic 
injection. 
     Concerning HIOs, these endodermal derivatives have also been shown to grow 
successfully on tube shaped PGA/PLLA scaffolds and integrate in vivo (Finkbeiner et al., 
2015) thereby advancing the use of these organoids as potential therapies for intestinal 
regeneration. Recently, HIOs with a functional enteric nervous system were generated by 
combining the HIOs with hPSC-derived neural crest cells. These organoids after in vivo 
transplantation formed neuroglial structures and had electrochemical coupling that regulated 
waves of propagating contraction. Despite the successful engraftment of the cells, their 
phenotype appears to be immature and more similar to the foetal gut, indicating that further 
optimisation is required (Workman et al., 2016).  
     The other endodermal organ which has been shown to benefit from cell based therapy is 
the pancreas. Indeed, islet transplantation (see introduction) has already established the 
interest of such approach for treatment of diabetes. In parallel, several groups have shown 
that pancreatic cells generated from hPSCs can alleviate diabetes in a mouse model (Jiang 
et al., 2007; Pagliuca et al., 2014; Rezania et al., 2014). Based on these promising results, 
the biotechnology company Viacyte has developed a major program aiming to transplant 
hESC-derived pancreatic progenitors encapsulated in a bag in patients with advanced Type 1 
diabetes. The use of pancreatic progenitors allows the production of functional cells in vivo 
thereby avoiding the lack of functional maturation associated with in vitro differentiation, while 
the encapsulation device protects cells against immune rejection and precludes risks 
associated with abnormal growth. Extensive animal model experiments have demonstrated 
the efficacy of this approach and the first human clinical trial is currently ongoing. This trial 
which is one of the most advanced using hPSC derivatives has enrolled 20 patients to confirm 
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the safety of this approach and to evaluate the quantity of cells necessary for maximum 
efficacy. Interestingly, recent information seems to suggest that the encapsulation device 
could present some challenges. Indeed, the encapsulation device requires extensive 
vascularisation without inducing fibrosis of surrounding tissues to enable long term functioning 
of the pancreatic cells. Nonetheless, this trial represents the first of its kind and there is no 
doubt this program and other initiatives such as Semma therapeutics will drive the field 
towards the development of novel therapies against diabetes.  
     To conclude this part, endodermal derivatives have generated promising results in 
preclinical models for cell based therapy applications while pancreatic cells have already 
reached the clinic. Nonetheless, additional studies are still needed to improve encapsulation 
method and also to produce a large quantity of cells in conditions compatible with the clinic.  
 
 
Current Challenges for Basic Studies and Clinical Applications 
Variation Between hPSCs Lines  
Variability in capacity of differentiation between hPSC lines is a major challenge and while the 
origin of this limitation remains unclear, genetic mechanisms appear to be a leading cause 
(Ortmann and Vallier, 2017). Nonetheless, endoderm differentiation seems to be particularly 
affected by this phenomenon. Indeed, while current protocols have been proven to work in 
multiple labs, endoderm differentiation remains strenuous, mainly due to the inductive nature 
of this process. Contrary to neuroectoderm specification which results from the inhibition of 
signaling pathways opposing differentiation, endoderm specification is driven by the inductive 
activity of Activin/Nodal signaling, which plays a central role in establishing the entire 
transcriptional network characterising endoderm cells. This role is obscured by the essential 
and apparently contradicting role of Activin signaling in maintaining pluripotency (Pauklin and 
Vallier, 2015). Thus, any factors affecting the level of Activin signaling or its efficacy can impact 
on the differentiation efficiency and increase contamination by undifferentiated cells. 
Furthermore, multiple factors can influence endoderm specification some of which are difficult 
to control. Firstly, cell density and size of plated colonies can interfere with the necessary EMT 
process characterising endoderm differentiation. Of note, this EMT also precludes 
differentiation from single cells and thus easy quantification of cell population.  Secondly, the 
stability and quality of recombinant growth factors can interfere with the inductive nature of 
Activin. Thirdly, the composition of the extracellular matrix can interfere with differentiation. 
For example, Matrigel contains high levels of TGF-β, which can interfere with Activin/Nodal 
signaling. Lastly, the endogenous levels of key growth factors including Nodal which level of 
expression could vary between different hiPSC lines (Ortmann and Vallier, 2017). 
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Consequently, all these parameters need to be optimised in each lab and for each individual 
hPSC line to obtain a robust and homogeneous differentiation. Of note, the development and 
more importantly the standardisation of chemically defined culture such as the E8 culture 
system is also helping to decrease these variability issues, while allowing a better control of 
differentiation conditions. In addition, protocols for deriving self-renewing endodermal 
progenitors (Cheng et al., 2012) and foregut stem cells (Hannan et al., 2013a) could help to 
bypass the limited differentiation capacity of some hPSCs lines. Indeed, these multipotent 
endodermal cells can be isolated from heterogeneous differentiation and then expended 
almost indefinitely thereby bypassing the need of constantly differentiating hPSCs.  
 
 
Functional Maturation 
Despite the advances in generating these cell types in vitro, the hPSC-derived cells display a 
foetal signature as opposed to their mature adult counterparts. This lack of functionality 
represents a limitation especially for specific in vitro applications such as toxicology screens 
or modeling of chronic disorders. Importantly, the lack of basic knowledge concerning the 
mechanisms controlling organ maturation especially in human, have hindered the further 
optimisation of current protocols. Consequently, new developments are often based on a trial 
and error approach. In addition, an increasing number of studies now utilises the development 
of 3D culture systems where multiple cell types can be cultured together. Indeed, most 
endoderm cell types work in a cooperative way, receiving signals from neighbouring cells in a 
3D environment. Of particular interest, endothelial and mesenchymal cells often provide 
important support for cellular function of endoderm derivatives. Accordingly, several groups 
have established 3D co-culture system to differentiate liver cells  (Dye et al., 2015; Gieseck et 
al., 2014; Ogawa et al., 2015; Sampaziotis et al., 2015a; Takebe et al., 2014) or pancreatic  β-
cells (Chmielowiec and Borowiak, 2014) and  lung organoids  (Franzdóttir et al., 2010). 
Nonetheless, such systems seem to improve function of the endodermal cells without 
conferring full maturation. Furthermore, 3D culture systems are more complex to set up while 
cells of interest are more difficult to access for phenotyping analyses, thereby precluding high 
throughput applications. GMP conditions can also be difficult to achieve despite recent 
progress in the development of artificial Matrigel based on PGA/PLLA scaffolds (Finkbeiner, 
2015). Using simpler systems that generate a pure population of endoderm derivatives 
enables a greater focus on specific biological aspects and direct comparison to primary tissue. 
These challenges highlight the need to perform further basic research to unravel the factors 
and biology involved in maturing functional cell types in endodermal organs.  
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     A solution to these challenges could be provided by transdifferentiation or forward 
programming approaches. These methodologies have been applied successfully to bypass 
the requirements for functional maturation in vitro for pancreas, intestine and liver cells 
(Benthuysen et al., 2016; Huang et al., 2014; Miura and Suzuki, 2017). Of particular interest, 
Du and colleagues used up to 7 hepatic factors including HNF1A, HNF4A and HNF6 along 
with the maturation factors ATF5, PROX1 and CEBPA to generate hiHeps from fibroblasts. 
The resulting cells display the hallmarks of primary hepatocytes including expression of phase 
I and phase II drug-metabolising enzymes as well as phase III drug transporters. Furthermore, 
these cells can repopulate the liver in vivo, expressed albumin and showed CYP enzyme 
activity (Du et al., 2014). These encouraging results and provide a proof of principle that such 
approach could bypass the need of laborious and lengthy culture systems of differentiation. 
Nonetheless, these methods are generally very complex, rely on proprietary media difficult to 
obtain and work specifically on embryonic fibroblasts. In addition, there are specific aspects 
associated with endodermal cells which make the transdifferentiation approach particularly 
challenging when compared to other cell types such as neurons. Indeed, endoderm cells are 
often quiescent while proliferative intermediates equivalent to neuronal stem cells are difficult 
to identify or to expand. Furthermore, endoderm cells are often epithelial cells that depend on 
strong cell to cell interactions, precluding single cell isolation or purification. Thus, 
transdifferentiation methods need to be extremely efficient or include oncogenes promoting 
proliferation with the risk of affecting basic cellular biology and normal function of the cells. 
Finally, there is currently no culture system to grow primary endodermal derivatives such as 
hepatocytes or β-cells. Thus, even extremely efficient methods of reprogramming could only 
produce cells losing rapidly their function. 
     To conclude, generating fully functional cells from hPSCs remains a challenge which can 
be alleviated only partially by 3D culture systems and transdifferentiation approaches. Only a 
better understanding of the mechanisms orchestrating functional maturation of endodermal 
organ will enable to improve current protocols of differentiation. 
 
 
Conclusions and Perspectives 
The field of stem cell biology and regenerative medicine has made considerable progress over 
the last decade in developing protocols for the production of a diversity of endoderm 
originating cell types from hPSCs. We can now produce liver, pancreas, gut (intestinal, 
stomach, colon), lung and thyroid cells (Agarwal et al., 2008; Cai et al., 2007; Dye et al., 2015; 
Jacob et al., 2017; McCauley et al., 2017; Ogawa et al., 2015; Sampaziotis et al., 2015a; Si-
tayeb et al., 2010; Snoeck, 2015; Song et al., 2009; Sullivan et al., 2010). Our knowledge of 
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basic developmental biology has been essential for the generation of these protocols. 
Importantly, methods of differentiation are now converging based on common standards for 
cell characterisation and culture systems. Consequently, hPSC endodermal derivatives are 
starting to be used by a growing number of groups to uncover novel mechanisms either 
controlling development or disease.  
     The main obstacle in the field of disease modeling and regenerative medicine remains the 
lack of functionality of the different cell types generated. This is partly due to our limited 
understanding of the mechanisms driving organ maturation in humans, especially as there is 
growing evidence that the molecular events that drive these processes could diverge between 
species (Snoeck, 2015). Thus, further basic studies are crucial for the development of novel 
approaches for the generation of fully functional cells from hPSCs. More specifically, it will be 
essential to identify signaling pathways and transcription factors that drive functional 
maturation of endoderm cells such as hepatocytes and β-cells.  
     Importantly, many organs in the body such as the intestine, muscle and hematopoietic 
system have resident adult stem cell populations necessary for tissue homeostasis and repair. 
Thus, organoids generated from primary tissues have been proposed as an alternative to 
hPSCs for producing liver, pancreatic, gut and lung cells in vitro. Many labs have described 
the generation of organoids from primary tissue including the intestine, liver and pancreas 
(Broutier et al., 2016; Rookmaaker et al., 2015). These systems can also aid in disease 
modeling (Schwank et al., 2013) and drug screening (Dekkers et al., 2013). However, the 
capacity/origin of other primary systems still requires further characterisation. For example, 
hepatocyte like cells produced from liver organoids can be used for modeling disease but their 
functionality remains limited (Broutier et al., 2017; Huch et al., 2015). The same applies to 
pancreatic organoids which originate from the pancreatic duct and which have a limited natural 
capacity of differentiation toward β-like cells. Beyond these technical aspects, primary 
organoids and hiPSC-derived endodermal organs provide a complementary system. Indeed, 
hPSC-derived cells can be used to model embryonic development and early organogenesis, 
while primary organoids could provide a platform to study functional maturation of specific cell 
types by comparison of foetal vs adult organoids derived from the same organ. In addition, 
hPSCs allow the study of disease progression while organoids provide information on end 
stage disease. Finally, hPSCs from the same donor can be differentiated into a diversity of 
cell types which is extremely challenging from organoids. Thus, the two systems could 
advantageously complement each other to study disease and development. 
     To conclude, the advances made in producing endodermal cell types is offering new 
opportunities to investigate developmental regulations and to uncover disease mechanisms 
impossible to study before. Moreover, endoderm derived cell types hold unique promises for 
regenerative medicine of diseases currently incurable. Nonetheless, key challenges remain to 
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be addressed to fulfil this potential. Therefore, the constant effort from the stem cell field must 
continue not only on clinical applications but also on basic studies aiming to understand basic 
characteristics of endodermal organ development. 
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Figure Legends 
Figure 1. Endoderm Derivatives Generated from hPSCs 
Schematic representation of differentiation of hPSCs into endoderm cell types and signaling pathways 
required for their generation. Key transcription factors expressed by each lineage is also outlined. 
 
Figure 2. Endoderm Derivatives for Clinical Application and Disease Modeling 
Schematic overview of translational application of hPSCs-derived endoderm cell types. hPSC-derived 
endoderm cells can be used to model genetic disorders, infectious disease, validate genes associated 
with disease and drug screening. Additionally, they can be used for cell therapy.  
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Table 1. Protocols to Generate Endoderm Cells from hPSCs 
Factors used  Markers Expressed Cells Generated Reference 
FBS, Activin A SOX17, FOXA2, 
GATA4, CXCR4 
Hepatocytes, 
Pancreatic cells 
(Agarwal et al., 2008; 
D’Amour et al., 2005, 2006) 
FCS, Activin A, 
FGF2 or WNT3A 
SOX17, HNF3β, 
CXCR4, HNF4α, α1-
antitrypsin and αFP 
Hepatocytes (Brolén et al., 2010) 
SR, Activin A  SOX17, FOXA2, Hepatocytes (Kubo et al., 2004) 
Activin A, 
LY294002 
SOX17, FOXA2, 
GSC, GATA4, 
GATA6 
In vivo transplantation 
showed expression of 
hepatic, lung and 
intestinal markers 
(McLean et al., 2007) 
Activin A, BMP4 SOX17, FOXA2,  
CXCR4 
Pancreatic progenitors (Teo et al., 2012) 
Activin A, 
LY294002, 
FGF2, BMP4 
SOX17, FOXA2, 
GSC, GATA4, N-Cad 
Hepatocytes (Touboul et al., 2010) 
Activin A, bFGF, 
BMP4, VEGF 
SOX17, FOXA2 Pancreatic cells (Nostro et al., 2011) 
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Table 2.  Markers/Function Displayed in Endoderm Derivatives Generated from hPSCs 
Cell Type Markers Expressed Function Displayed Reference 
Hepatocytes Fetal hepatocytes: HNF4α, HNF6, 
CEBPα, PROX1, ASGPR1, AFP 
 
Adult hepatocytes: HNF4α, ALB, 
AAT, CYP3A4, CK8, CK18 
 Albumin secretion 
 Glycogen storage 
 Urea metabolism 
 LDL uptake 
 Cytochrome P450 
activity 
(Agarwal et al., 2008; Brolén et al., 
2010; Cai et al., 2007; Hannan et al., 
2013b; Mallanna and Duncan, 2013; Si-
tayeb et al., 2010; Siller et al., 2015; 
Song et al., 2009; Sullivan et al., 2010; 
Touboul et al., 2010) 
Cholangiocytes Cholangiocyte progenitors: SOX9, 
HNF1b, CK19 
 
Adult Cholangiocytes: CK7, CFTR, 
SCR, SSTR2, AQP1, AE2 
 Rhodamine 123 
transport by MDR1 
receptor 
 CFTR activity 
 GGT secretion 
 ALP activity 
 Transport of bile acid 
 Hormonal response  
(Dianat et al., 2014; Ogawa et al., 2015; 
Sampaziotis et al., 2015a) 
Pancreatic β-
cells 
Pancreatic progenitors: PDX1, 
NKX6.1, SOX9, FOXA2, HNF1B, 
HNF4A  
 
Beta cells: PDX1, NKX6.1, NGN3, 
INS, GCG, SST 
 Insulin secretion upon 
glucose stimulation 
 
(Cheng et al., 2012; Chmielowiec and 
Borowiak, 2014; D’Amour et al., 2006; 
Jiang et al., 2007; Pagliuca et al., 2014; 
Rezania et al., 2014) 
Lung cells Proximal/Airway progenitors: 
NKX2.1, FOXA2, SOX2, P63 
 
Proximal Airway cells: SCGB1A1, 
SCGB3A2, FOXJ1, P63, KRT5, 
MUC5AC 
 
Distal/Alveolar progenitors: 
NKX2.1, FOXA2, SOX9, FOXP2, 
ETV5, SFTPC 
 
Distal/Alveolar cells: SFTPC, 
PDPN, AQP5, HOPX 
 Apical localization and 
functionality of CFTR 
 Surfactant protein B 
(SP-B) uptake and 
release 
 Presence of lamellar 
bodies 
 Surfactant protein C 
(SP-C) secretion 
 Ciliogenesis and motile 
cilia 
(Dye et al., 2015; Firth et al., 2014; 
Ghaedi et al., 2013; Gotoh et al., 2014; 
Huang et al., 2013; Jacob et al., 2017; 
Longmire et al., 2012; McCauley et al., 
2017; McIntyre et al., 2014; Mou et al., 
2012; Wong et al., 2012) 
 Gut Intestinal stem cells: LGR5, ASCL2 
 
Differentiated intestinal cell types: 
VIL, MUC2, LYZ, CHGA 
 
 
 
 
Stomach progenitors: SOX2, 
PDX1, LGR5, SOX9, GATA4 
 
Differentiated stomach cell types: 
MUC5AC, MUC6, TFF1/3, GKN1, 
TFF2  
 Presence of apical 
microvilli 
 Functional peptide 
transport of enterocytes 
 Mucin secretion by 
goblet cells 
 
 
 Pathophysiological 
response to H. Pylori 
infection  
(Finkbeiner et al., 2015; Fordham et al., 
2013; Munera et al., 2017; Spence et 
al., 2011; Watson et al., 2014; 
Workman et al., 2016) 
 
 
 
 
 
 
(McCracken et al., 2014) 
 
 
 
